ViRexx completes enrollment, treatment of volunteers in phase 1 trial for HepaVaxx B Vaccine

By Lisa Kerner

Charlotte, N.C., Aug. 9 - ViRexx Medical Corp. said enrollment and vaccination of 15 healthy volunteers is completed in its phase 1 trial for HepaVaxx B Vaccine, the lead candidate from the company's novel Chimigen vaccine platform.

There were no significant adverse events associated with the treatment.

"Establishing a strong safety profile for this novel therapeutic vaccine is critical to the advancement of our Chimigen platform," chief scientific officer Lorne Tyrrell said in a company news release.

"We intend to continue to monitor volunteers in order to complete the safety assessment for this study."

In preclinical testing, HepaVaxx B Vaccine has produced both cellular and humoral immune responses, believed to be effective in clearing the virus from patients with chronic hepatitis B infection.

Hepatitis B infects one out of every three people worldwide, according to The World Health Organization.

ViRexx is an Edmonton, Alta.-based biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and chronic viral infections.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.